Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.47 |
| ▸ | APP | P05067 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8110644 | 0.93 | AKR1C1 (0.59) | AKR1C1AKR1C3AKR1C2OPRM1HDAC1 | |
| SCHEMBL3520383 | 0.91 | AKR1C1 (0.62) | AKR1C1HDAC1SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL8347528 | 0.87 | OPRM1 (0.45) | AKR1C1AKR1C3AKR1C2OPRM1HDAC1 | |
| SCHEMBL3814554 | 0.86 | SLC6A3 (0.47) | AKR1C1AKR1C3AKR1C2OPRM1HDAC1 | |
| SCHEMBL14790320 | 0.82 | AKR1C3 (0.42) | AKR1C1AKR1C3AKR1C2APPCYP2C9 | |
| SCHEMBL7744850 | 0.80 | OPRM1 (0.56) | OPRM1HDAC1HDAC3HDAC7HDAC2 | |
| SCHEMBL15546631 | 0.80 | KDM4E (0.51) | AKR1C1AKR1C3AKR1C2CYP2C19 | |
| SCHEMBL6391 | 0.78 | AKR1C1 (0.83) | AKR1C1CYP2C19 | |
| SCHEMBL31016196 | 0.78 | AKR1C1 (0.83) | AKR1C1CYP2C19 | |
| SCHEMBL7366815 | 0.77 | HDAC1 (0.50) | OPRM1HDAC1SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957229-B2 | Amido compounds and their use as pharmaceuticals | INCYTE HOLDINGS CORPORATION (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170334847-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION | 2017-11-23 | — | — | US | disclosed |
| US-9670154-B2 | Amido compounds and their use as pharmaceuticals | INCYTE HOLDINGS CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| EP-2963021-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Holdings Corporation (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20150329561-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION | 2015-11-19 | — | — | US | disclosed |
| CN-101001842-B | Amido compounds and the application as medicine thereof | INCYTE CORP. (US) | 2015-10-07 | — | — | CN | disclosed |
| US-9126927-B2 | Amido compounds and their use as pharmaceuticals | INCYTE HOLDINGS CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| EP-1756063-B1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2015-07-08 | — | — | EP | disclosed |
| EP-2421826-B1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-7776874-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1756063-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080255154-A1 | Cycloalkylcarbonyl-3H-spiro[2-benzofuran-1,3'-pyrrolidin]-3-ones: N-methyl-5-[4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'-yl]carbonyl}cyclopropyl)phenyl]pyridine-2-carboxamide; 11- beta hydroxyl steroid dehydrogenase type 1 inhibitors; mineralcorticoid receptor antagonists; diabetes | INCYTE CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| EP-1499319-B1 | BICYCLO 4.4.0 ANTIVIRAL DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2007-12-05 | — | — | EP | disclosed |
| US-7304081-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-02 | — | — | US | disclosed |
| CN-101001842-A | Amido compounds and their use as pharmaceuticals | INCYTE CORP (US) | 2007-07-18 | — | — | CN | disclosed |
| EP-1756063-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20050282858-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-22 | — | — | US | disclosed |
| WO-2005110992-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334847-A1 | Amido Compounds And Their Use As Pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | AKR1C1 38/4885AKR1C3 43/4885AKR1C2 31/4885 |
| US-20050282858-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | AKR1C1 38/4885AKR1C3 43/4885AKR1C2 31/4885 |
| US-20080255154-A1 | Cycloalkylcarbonyl-3H-spiro[2-benzofuran-1,3'-pyrrolidin]-3-ones: N-methyl-5-[4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'-yl]carbonyl}cyclopropyl)phenyl]pyridine-2-carboxamide; 11- beta hydroxyl steroid dehydrogenase type 1 inhibitors; mineralcorticoid receptor antagonists; diabetes | HSD11B1, NR3C2, SRD5A1 | AKR1C1 18/4885AKR1C3 23/4885AKR1C2 19/4885 |
| US-20150329561-A1 | Amido Compounds And Their Use As Pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | AKR1C1 38/4885AKR1C3 43/4885AKR1C2 31/4885 |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | AKR1C1 38/4885AKR1C3 43/4885AKR1C2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.